FDA Panel Will Meet Nov. 30 To Discuss Merck’s Oral COVID-19 Drug

FDA’s antimicrobial drug advisers will meet Nov. 30 to vote on whether the agency should authorize Merck and Ridgeback Biotherapeutics’ investigational antiviral drug, molnupiravir, to treat mild-to-moderate COVID-19 in adults who are at high risk for progressing to severe disease, FDA announced Thursday (Oct. 14). If authorized for emergency use, Merck asserts molnupiravir would be the first oral antiviral for COVID-19 . The U.S. government and Merck have entered into a procurement agreement under which the company will supply the...